At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 98 enrolled
Drug / intervention
Phenazopyridinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Control Trial Assessing Pyridium for Post-Sling Urinary Retention
In Brief
A Phase 4 clinical trial evaluating Phenazopyridine for Urinary Retention. Completed, enrolled 98 participants across 1 site.
Detailed Summary
There has been preliminary data showing that pyridium can decrease the risk of difficulty urinating after midurethral sling. This study is designed to have two groups of patients. One group will receive pyridium pre-operatively, while the other group will have routine preoperative care. Both groups will have their bladder tested prior to going home. It will be evaluated if there is a difference in the difficulty to urinate post-operatively in both groups.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Retention
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartOct 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedOct 5, 2017
Enrollment StartOct 24, 2017
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.7 years ago
Interventions
Phenazopyridinedrug
to be given preoperatively